Literature DB >> 911167

Induction of drug photosensitization in man after parenteral exposure to hematoporphyrin.

G L Zalar, M Poh-Fitzpatrick, D L Krohn, R Jacobs, L C Harber.   

Abstract

Two patients had acute phototoxic reactions after intravenous injections of hematoporphyrin (7 mg/kg) and exposure to light. These reactions were characterized by pain, redness, and swelling of affected sites. Controlled clinical studies were instituted using known types and amounts of light to ascertain the degree of photosensitivity at various time intervals after drug administration. In addition, action spectrum studies elicited a peak response at 405 nm (+/- 5 nm). Plasma hematoporphyrin concentration was approximately 520 microgram/100 ml one hour after hematoporphyrin infusion and it gradually declined during a period of 42 days with a biphasic diminution that suggested the existence of at least two pools of hematoporphyrin with half-life decay times of 16 hours and 12 days. beta-carotene was administered to ascertain whether or not the phototoxic response could be modified. It is suggested that a degree of protection was obtained that was insufficient to protect the patient.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 911167

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  13 in total

1.  Photodynamic therapy of experimental colonic tumours with 5-aminolevulinic-acid-induced endogenous porphyrins.

Authors:  K Orth; K König; F Genze; A Rück
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

2.  Possible advantages of aluminum-chloro-tetrasulfonated phthalocyanine over hematoporphyrin derivative as a photosensitizer in photodynamic therapy.

Authors:  K Koshida; H Hisazumi; K Komatsu; A Hirata; T Uchibayashi
Journal:  Urol Res       Date:  1993

3.  Haematoporphyrin and OO'-diacetylhaematoporphyrin binding by serum and cellular proteins. Implications for the clearance of these photochemotherapeutic agents by cells.

Authors:  A Smith; T Neuschatz
Journal:  Biochem J       Date:  1983-08-15       Impact factor: 3.857

4.  Differential interaction of porphyrins used in photoradiation therapy with ferrochelatase.

Authors:  H A Dailey; A Smith
Journal:  Biochem J       Date:  1984-10-15       Impact factor: 3.857

5.  Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model.

Authors:  J Bedwell; A J MacRobert; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

6.  Tumour-localising and -photosensitising properties of a novel zinc(II) octadecylphthalocyanine.

Authors:  C Ometto; C Fabris; C Milanesi; G Jori; M J Cook; D A Russell
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

7.  Liposome- or LDL-administered Zn (II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and phototherapeutic efficiency.

Authors:  E Reddi; C Zhou; R Biolo; E Menegaldo; G Jori
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

8.  Pharmacokinetic studies with zinc(II)-phthalocyanine in tumour-bearing mice.

Authors:  E Reddi; G Lo Castro; R Biolo; G Jori
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

9.  Correlation of distribution of sulphonated aluminium phthalocyanines with their photodynamic effect in tumour and skin of mice bearing CaD2 mammary carcinoma.

Authors:  Q Peng; J Moan
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

10.  Hexadecafluorinated zinc phthalocyanine: photodynamic properties against the EMT-6 tumour in mice and pharmacokinetics using 65Zn as a radiotracer.

Authors:  R W Boyle; J Rousseau; S V Kudrevich; M Obochi; J E van Lier
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.